Overview for Biologics GxP Applications
Regulatory requirements necessitate that biologics drug products be QC tested using methods that are robust and have been appropriately qualified and validated under GMP conditions. The Octet BLI instrument is a reliable system that facilitates method development for in-process testing and lot release analytical methods that can be easily transferred to QC. The ease of use and high through-put features allows for enhanced productivity of up to 40X over ELISA and up to 16X over select SPR instruments for certain GMP applications.
Fc receptor binding assays on the Octet system
The safety and efficacy of a therapeutic monoclonal antibody can be greatly impacted by its ability to bind to both the target and to the FcγR. Antibodies are often selected based on their binding properties to FcγRs. They are sometimes engineered to achieve desired FcγRs binding properties. As a result, the assessment of binding affinities of these antibodies to FcγRs is an integral part of biotherapeutic development processes.
- Octet systems offer high throughput and sensitive methods for Fc receptor binding analysis
- A variety of biosensor surfaces are available and allow for flexibility and rapid optimization of assay format
Ligand binding potency assays on the Octet platform
Reproducible and accurate relative ligand binding potency methods can be developed using analytical technologies. These methods can be used to assess lot-to-lot variability by monitoring either the drug binding response or the kinetics of binding including affinity constants. These parameters typically change with changing stability of the different lots of the drug. As a result, an appropriate method for lot release must be stability indicating. Due to its ease of use and fast time to results, the Octet technique is increasingly becoming attractive for the development of methods for assessing the potency of drug candidates.
- Readily accommodates the use of DOEs to rapidly develop robust potency measurement methods
- Develops relative affinity constant or response signals comparability studies for potency measurements
Titer determination on the Octet platform
Titer and protein concentration determination is a critical process in the development of biologics drug molecules. The active protein concentration can be used to determine the potency of the drug molecule. While ELISA and especially HPLC are commonplace techniques for titer and protein concentration determination, techniques that are more robust to cell culture and media are especially desirable as they can be easily adopted in both upstream and downstream processes during the development of the drug molecule.
- A full plate (96 samples) of IgG titer can be analyzed in as little as two minutes
- Sample plate format allows for the use of crude and non-purified samples
- Automation capable Octet HTX and Red 384 allow for walkaway high throughput analysis
Resources of GxP Applications
Application Note Validated Quantitation and Activity Assay of Antibody Fragment Molecule (Fab) for Process Development and Quality Control
The group was able to develop a working Fab activity assay on the Octet RED system in less than a week. Relative to the overnight incubation and four-hour assay time of their ELISA protocol, the Octet assay provided an analysis time of only one hour per 96-well microplate, including sample preparation time. This Octet assay was used to monitor Fab activity for all process development studies.
Application Note Analysis of Fc-gamma Receptor-IgG Interactions on the Octet Platform
Fc gamma receptors (FcγRs) are membrane glycoproteins with affinity for the Fc region of immunoglobulin G (IgG). FcγRs expressed on the surface of immune effector cells play a key role in initiating Fc effector functions such as antibody-mediated cell-dependent cytotoxicity (ADCC)1, which is a major mechanism of action of therapeutic monoclonal antibodiesRead more
Application Note Analysis of FcRn-Antibody Interactions on the Octet Platform
The Fc region of human IgG contributes to a number of beneficial biological and pharmacological characteristics of therapeutic antibodies.Read more
Application Note Octet Potency Assay: Development, Qualification and Validation Strategies
In this application note, we discuss the strategies for the development and validation of a potency assay using Octet® systems. We have highlighted the Octet system’s ease-ofuse and fast time to results by showcasing strategies for the development and validation of a method for evaluating the binding of an Fc gamma receptor III molecule to the widely characterized NISTmAb.Read more
Application Note Enhancing Efficiency and Economics in Process Development and Manufacturing of Biotherapeutics
Scientific Poster High Productivity and process economy in GxP applications with the Octet platform
Using the label-free optical technique of Bio-Layer Interferometry (BLI), the Octet® platform provides real time analysis of biomolecular interactions.Read more
White Paper Octet platform: a complete solution for lot release and in-process testing of biologics in GxP laboratories
Bio-Layer Interferometry (BLI) is an optical analytical technique that analyzes the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip and an internal reference layer (Figure 1A). Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real time (Figure 1A and 1B). The binding between a ligand immobilized on the biosensor surface and an analyte in solution produces an increase in optical thickness measured as a wavelength shift, Δ λ (Figure 1C).Read more
Application Overview Quality control of biotherapeutics using Octet systems
Bio-Layer Interferometry (BLI) has been rapidly adopted as an important analytical tool in laboratories that work with biological molecules, either as drug products, vaccines, or diagnostic reagents.Read more
Application Overview Octet Systems: Modernize biopharmaceutical QC testing to increase efficiency
Quality control of biological products to support clinical trials and post market assay activities require the evaluation of multiple critical product attributes.Read more